| Liquid biopsy: monitoring cancer-genetics in the blood E Crowley, F Di Nicolantonio, F Loupakis, A Bardelli Nature reviews Clinical oncology 10 (8), 472-484, 2013 | 1912 | 2013 |
| Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, ... New England Journal of Medicine 381 (17), 1632-1643, 2019 | 1215 | 2019 |
| FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular … C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ... The Lancet Oncology 16 (13), 1306-1315, 2015 | 1115 | 2015 |
| Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ... New England Journal of Medicine 371 (17), 1609-1618, 2014 | 1102 | 2014 |
| Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015 | 1090 | 2015 |
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ... British journal of cancer 101 (4), 715-721, 2009 | 706 | 2009 |
| Primary tumor location as a prognostic factor in metastatic colorectal cancer F Loupakis, D Yang, L Yau, S Feng, C Cremolini, W Zhang, MKH Maus, ... Journal of the National Cancer Institute 107 (3), dju427, 2015 | 525 | 2015 |
| PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ... J Clin Oncol 27 (16), 2622-2629, 2009 | 506 | 2009 |
| Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ... Journal of clinical oncology 25 (10), 1247-1254, 2007 | 379 | 2007 |
| Quantitative evidence for early metastatic seeding in colorectal cancer Z Hu, J Ding, Z Ma, R Sun, JA Seoane, J Scott Shaffer, CJ Suarez, ... Nature genetics 51 (7), 1113-1122, 2019 | 354 | 2019 |
| Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and subgroup analyses from … J Tabernero, A Grothey, E Van Cutsem, R Yaeger, H Wasan, T Yoshino, ... Journal of Clinical Oncology 39 (4), 273, 2021 | 322 | 2021 |
| Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by … G Masi, F Loupakis, L Pollina, E Vasile, S Cupini, S Ricci, IM Brunetti, ... Annals of surgery 249 (3), 420-425, 2009 | 321 | 2009 |
| Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial G Masi, F Loupakis, L Salvatore, L Fornaro, C Cremolini, S Cupini, ... The lancet oncology 11 (9), 845-852, 2010 | 307 | 2010 |
| High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ... The oncologist 13 (12), 1270-1275, 2008 | 305 | 2008 |
| Assessment of a HER2 scoring system for colorectal cancer: results from a validation study E Valtorta, C Martino, A Sartore-Bianchi, F Penaullt-Llorca, G Viale, ... Modern Pathology 28 (11), 1481-1491, 2015 | 281 | 2015 |
| Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial S Siena, M Di Bartolomeo, K Raghav, T Masuishi, F Loupakis, ... The Lancet Oncology 22 (6), 779-789, 2021 | 270 | 2021 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with … C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ... The Lancet Oncology 21 (4), 497-507, 2020 | 254 | 2020 |
| FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer F Loupakis, C Cremolini, L Salvatore, G Masi, E Sensi, M Schirripa, ... European journal of cancer 50 (1), 57-63, 2014 | 242 | 2014 |
| Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis G Masi, E Vasile, F Loupakis, S Cupini, L Fornaro, G Baldi, L Salvatore, ... Journal of the National Cancer Institute 103 (1), 21-30, 2011 | 232 | 2011 |
| Cancer dormancy: a model of early dissemination and late cancer recurrence D Páez, MJ Labonte, P Bohanes, W Zhang, L Benhanim, Y Ning, ... Clinical Cancer Research 18 (3), 645-653, 2012 | 226 | 2012 |
chiara cremoliniFull Professor, University of PisaAdresse e-mail validée de unipi.it
